Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.
About Treat COVID-19
The FDA revised the emergency use authorization (EUA) of baricitinib to authorize barretinib alone to treat hospitalized adults and pediatric covid-19 patients aged 2 years or over who need auxiliary oxygen supply, noninvasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Reference resources:《FDA authorizes baricitinib alone as treatment for COVID-19 . Retrieved 2021-07-29》